COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, to advance proteome and proteogenome science and technology development through community resources (data and reagents), and to accelerate the translation of molecular findings into the clinic. This is achieved through extramural programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, collaborations with international organizations/institutions, and intramural reference laboratories such as the Antibody Characterization Lab and Clinical Proteomic Characterization Lab.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

Video Release: 47th Vice President of the United States Joseph R. Biden Jr. Speech at HUPO2017 Global Leadership Gala

The Human Proteome Organization (HUPO) has released a video of the keynote speech given by the 47th Vice President of the United States of America Joseph R. Biden Jr. at the HUPO2017 Global Leadership Gala. Under the gala theme “International Cooperation in the...


Request for Proposals (RFP S18-012) for Production of Affinity Binders

The National Cancer Institute Office of Cancer Clinical Proteomics Research, through its prime contract with Leidos Biomedical Research Inc.


Korea University Joins the International Efforts in Clinical Proteogenomics Cancer Research

The National Cancer Institute's (NCI) Office of Cancer Clinical Proteomics Research, part of the National Institutes of Health, and Korea University (KU) located in The Republic of Korea have signed a Memorandum of Understanding (MOU) in clinical proteogenomics cancer research. The MOU between NCI...


Rodriguez Recognized as Recipient of the MSSS AACC Chair’s Inspirational Award

Dr. Henry Rodriguez, director of the Office of Cancer Clinical Proteomics Research, has been recognized as the recipient of the Chair’s Inspirational Award by the Mass Spectrometry and Separation Sciences for Laboratory Medicine Division (MSSS), American Association for Clinical Chemistry (AACC).


Leaderboard Now Open: CPTAC’s DREAM Proteogenomics Computational Challenge

The National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to announce the opening of the leaderboard to its Proteogenomics Computational DREAM Challenge. The leadership board remains open for submissions during September 25, 2017 through October 8, 2017, with the...


NCI Releases Video: Proteogenomics Research - On the Frontier of Precision Medicine

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), part of the National Institutes of Health, announces the release of an educational video titled “Proteogenomics Research: On the Frontier of Precision Medicine."  Launched at the HUPO2017 Global...


Oral Squamous Cell Carcinoma Mutational Profile in Taiwanese Population

Oral squamous cell carcinoma (OSCC) is a major oral cancer subtype that is the fourth most common cancer affecting Taiwanese men. Despite known risk behaviors such as cigarette smoking, alcohol drinking, and betel nut chewing often indulged by Taiwanese men, the genetic contribution to the incidence...


47th Vice President of the United States Joseph R. Biden, Jr. to deliver keynote address at HUPO2017 Global Leadership Gala Dinner

The Human Proteome Organization (HUPO) and Prof Steve Pennington, UCD, chair of the organizing committee of HUPO2017 (the 16th HUPO World Congress) in...


CPTAC Collaborates with Molecular & Cellular Proteomics to Address Reproducibility in Targeted Assay Development

The journal Molecular & Cellular Proteomics (MCP), in collaboration with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), part of the National Institutes of Health, announce new guidelines and requirements for papers describing the development and...


CPTAC Team Releases Targeted Proteomic Assays for Ovarian Cancer

Pacific Northwest National Laboratory (PNNL) investigators in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), announces the public release of 98 targeted mass spectrometry-based assays for ovarian cancer research studies.  Chosen based on proteogenomic...


Pages